Connection
Edith Zemanick to Anti-Infective Agents
This is a "connection" page, showing publications Edith Zemanick has written about Anti-Infective Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.845 |
|
|
|
-
Hahn A, Burrell A, Chaney H, Sami I, Koumbourlis AC, Freishtat RJ, Crandall KA, Zemanick ET. Therapeutic beta-lactam dosages and broad-spectrum antibiotics are associated with reductions in microbial richness and diversity in persons with cystic fibrosis. Sci Rep. 2023 01 21; 13(1):1217.
Score: 0.673
-
VanDevanter DR, Zemanick ET, Konstan MW, Ren CL, Odem-Davis K, Emerman I, Young J, Mayer-Hamblett N. Willingness of people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trials. J Cyst Fibros. 2023 07; 22(4):652-655.
Score: 0.171